Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for Moderate to Severe Hidradenitis Suppurativa (Single-Arm, Phase 4)
ChiCTR2600121030Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in hidradenitis suppurativa (HS), sponsored by West China Hospital of Sichuan University. Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR or analogous). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on ChiCTR2600121030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121030.